4 Results for "

In situ IC50

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "In situ IC50" in MCE Product Catalog:

Cat. No.: HY-129121
CAS No.: 2055172-43-3
Purity:  98.76%
Target:  

MAGL

Research Areas:  

Neurological Disease

ML226 is a potent inhibitor of α/β hydrolase domain protein 11 (ABHD11), with in vitro and in situ IC50 values ​​of 15 and 0.68 nM, respectively. ML226 is an inhibitor of protein palmitoylthioesterase lysophospholipase 1 (LYPLA1) and LYPLA2. ML226 can be used for research related to neurological diseases .
loading...
    loading...
Cat. No.: HY-10294
CAS No.: 362505-84-8
Purity:  99.58%
Synonyms: SB-462795
Target:  

Cathepsin

Research Areas:  

Metabolic Disease Cancer

Relacatib (SB-462795) is a novel, potent, and orally active inhibitor of human cathepsins K, L, and V with Ki values of 41 pM, 68 pM, and 53 pM, respectively. Relacatib inhibits endogenous cathepsin K in situ in human osteoclasts and human osteoclast-mediated bone resorption with IC50 values of 45 nM and 70 nM, respectively. Relacatib inhibits bone resorption in vitro in human tissue as well as in cynomolgus monkeys in vivo .
loading...
    loading...
Cat. No.: HY-120252
CAS No.: 1831135-46-6
Purity:  98.7%
Target:  

Ser/Thr Protease

Research Areas:  

Neurological Disease

ABC44 is a potent serine hydrolase inhibitor with IC50s of 0.1 μM and 6.5 μM for palmitoyl protein thioesterase 1 (PPT1) in situ and in vitro, respectively. ABC44 can be used for researching infantile neuronal ceroid lipofuscinosis .
loading...
    loading...
Cat. No.: HY-10294R
CAS No.: 362505-84-8
Synonyms: SB-462795 (Standard)
Research Areas:  

Metabolic Disease Cancer

Relacatib (Standard) is the analytical standard of Relacatib (HY-10294). This product is intended for research and analytical applications. Relacatib (SB-462795) is a novel, potent, and orally active inhibitor of human cathepsins K, L, and V with Ki values of 41 pM, 68 pM, and 53 pM, respectively. Relacatib inhibits endogenous cathepsin K in situ in human osteoclasts and human osteoclast-mediated bone resorption with IC50 values of 45 nM and 70 nM, respectively. Relacatib inhibits bone resorption in vitro in human tissue as well as in cynomolgus monkeys in vivo .
loading...
    loading...